foxnews.com
Promising Breast Cancer Vaccine Shows Encouraging Results
A potential breast cancer vaccine targeting triple-negative breast cancer shows promising results in Phase 1 trials, offering a new preventative approach to this aggressive disease.
English
United States
HealthCancerResearchMedicineVaccine
Cleveland ClinicSociety For Immunotherapy Of CancerAmerican Cancer SocietyU.s. Department Of DefenseAnixa Biosciences
G. Thomas BuddVincent TuohyNicole Saphier
- What protein is the vaccine based on?
- The vaccine uses α-lactalbumin, a protein associated with lactation, as its target. This protein is chosen because it's absent in the breast tissue of most post-childbearing women but present in a significant percentage of triple-negative breast cancer cases.
- What were the results of the Phase 1 trial?
- The Phase 1 trial of the vaccine showed it was well-tolerated and produced an immune response in most patients. The next phase will evaluate the vaccine's effectiveness in preventing recurrence of triple-negative breast cancer.
- Who is funding and developing this vaccine?
- The research is a collaboration between Cleveland Clinic and Anixa Biosciences, funded by the U.S. Department of Defense. Anixa Biosciences plans to begin Phase 2 trials next year to further assess the vaccine's efficacy.
- What is the significance of this development?
- Experts, including Dr. Nicole Saphier, consider this development groundbreaking and exciting, potentially revolutionizing breast cancer care by focusing on prevention. The vaccine may significantly reduce breast cancer incidence and the associated burdens.
- What type of breast cancer does the new vaccine target?
- Researchers at Cleveland Clinic have developed a potential vaccine for triple-negative breast cancer, a highly aggressive form of the disease. The vaccine targets a protein specific to lactation, which is rarely present in older women's breast tissue but is found in high levels in many TNBC cases.